Answers are grounded in this paper and cite their sources.
To renew US competitiveness in clinical trials, the federal government launched Operation TrialBlazer in June 2026. Its proposed Expedited-IND Acceleration Pilot would enlist Qualified Research Institutions (QRIs) to help sponsors prepare investigational new drug (IND) applications for first-in-human studies. Because a successful IND does not guarantee a completed trial, we propose a testable, expanded QRI framework to support trial execution. First, build QRIs with standing networks that reuse contracts, data systems, and staff to lower marginal costs and enable performance measurement. Second, require QRIs to have capabilities that enable and assess site performance: human factors expertise and stakeholder co-design in protocol development; leading (not only lagging) indicators of trial performance; efficient, proportionate execution that preserves rigor and safety; and oversight by an independent trial performance monitoring board empowered to conduct in-person observations and interviews at trial sites. Third, qualify QRIs on demonstrated performance, with reciprocal obligations for sponsors. Fourth, renew QRIs using publicly reported, case-mix-adjusted metrics. The Food and Drug Administration and National Institutes of Health should jointly fund evaluations of this framework. Extending QRIs across the trial lifecycle is more likely than a pre-IND role alone to close the time and cost gaps that send research overseas.
No takes yet. Share an insight, caveat, or question.
Krishnan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: